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Gangliosldes are possibly very potent immunosuppressive molecules. Here we show that human amniotic fluid contains high concentrations of 
a number of previously unnoted, structurally complex and highly polar ganghosides These unusual molecules are present early m pregnancy (first 
trimester), increase in concentration with gestational age, and reach maximum levels (0.8 PM) at term. Smce similar ganghosides have been detected 
in human placenta, trophoblast. and amnion. we suggest that these molecules are shed into the amniotic fluid bathing these tissues. 
Shed ganghoside, Amniotic fluid 
1. INTRODUCTION 
During pregnancy, there is an intense proliferation of 
the haploidentical fetal allograft, which should result in 
its rejection. Why this does not occur remains an 
enigma. However, the maternal-fetal interface may 
have a role in prevention of fetal rejection [l-6], shed- 
ding immunosuppressive molecules which can be found 
in the amniotic fluid, which itself has immunosuppres- 
sive properties [7710]. One such class of immunosup- 
pressive molecules is the gangliosides, sialic acid-con- 
taining glycosphingolipids which are embedded in cell 
membranes by their ceramide portion. 
The shedding of cell surface membrane components 
such as gangliosides is characteristic of rapidly prolifer- 
ating cells [ 111. Therefore, gangliosides from the mater- 
nal-fetal system might be found in the amniotic fluid. 
Since the shedding of tumor gangliosides inhibits nor- 
mal cellular immune responses [ 121. we hypothesize that 
such shedding could likewise modify the immunological 
interaction between the fetus and the mother. The ob- 
ject of this study therefore was to characterize the gan- 
glioside content of human amniotic fluid. 
We expected the ganglioside composition of human 
amniotic fluid to reflect the ganglioside composition of 
the placenta, trophoblast, and amnion, in which the 
ganglioside G,, is predominant [13-l 61, because gangli- 
oside shedding generally reflects, qualitatively and 
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quantitatively, ganglioside synthesis [17]. To our sur- 
prise. we detected a series of structurally complex and 
highly polar gangliosides in human amniotic fluid as the 
major and almost exclusive components. 
2. MATERIALS AND METHODS 
Aliquots of amniotic fluid samples which had been obtained from 
pregnant women at 1640 weeks of gestation by transabdommal am- 
niocentesis under sterile conditions were studied. The samples were 
cooled to 4°C immediately and rapidly processed. 
After an mittal analysis of unfractionated ammotic fluid, all samples 
were fractionated by centrtfugation according to the scheme shown m 
Fig. 1 Cells (mostly epithelial) present in the ammotic fluid were 
removed by centrtfugation at 800 x g for 15 min at 4°C. and the 
supernate was recentrifuged at 8,000 x g for 15 min at 4°C. to remove 
cell fragments In some samples, particularly those obtained at the end 
of pregnancy. it was also possible to isolate surfactant as a floatmg 
white layer after centrifugation. To determine the qualitative and 
quantitative distribution of ganghosides in human amniotic fluid and 
its particulate fractions and m surfactant, each component was proc- 
essed separately under identical conditions 
2 2 Gunglrosidr pmfcation 
The total ganghostdes of the samples were purified by total hpid 
extraction, diisopropyl ether (DIPE)/l-butanol/aqueous phase parti- 
tion and Sephadex G-50 gel filtration as developed for the isolation 
ofgangliostdes from fluids [18,19]. Total lipid extracts were preparated 
usmg 2 ml chloroform/methanol (C:M) (1.1. v/v) per ml amniotic fluid 
and 20 ml C/M (1: 1. v/v) per gram of cells. cell fragments or surfactant. 
All samples were extracted twice The extracts were pooled and clari- 
fied by centrifugation (750 x g for 10 min at 4°C) to remove particu- 
late matter, reduced to approximately l/4 of then original volume by 
rotary evaporation, and cooled to -20°C. Additional msoluble mate- 
rial was removed by centrifugation and the final total lipid extracts 
were taken to dryness 
Partitionmg was accomplished by dispersing the dried total lipid 
extracts in DIPE/l-butanol (60:40, v/v). with several minutes of 
vortexing and bath somcation. 4 ml of the organic solvent mixture was 
used for the total lipid extract of each 10 ml of amniotic fluid and 20 
ml for the total lipid extract of each gram of cells. cell fragments. or 
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surfactant Next. distilled Rater (for ammotic fluid) or 0.1% aqueous 
NaCl (for cells, cell fragments and surfactant). one half of the volume 
of the organic solvent, was added with vortexing and somcation. After 
centrifugation at 750 x g for 10 min to separate the two phases, the 
upper organic phase (contammg the neutral hptds and phospholipids) 
was carefully removed. The ganglioside-contammg lower aqueous 
phase was re-extracted twice with the original volume of fresh orgamc 
solvent. and the final aqueous phase was lyophilized. The samples 
were redissolved m a small volume of distilled water. somcated. and 
subjected to Sephadex G-50 gel filtration. usmg distilled water as the 
elutmg solvent. Gangliosides were recovered m the void volume peak, 
lyophthzed. redissolved m a small volume of C/M (I.1 1, and centri- 
fuged to remove insoluble restdual protems co-extracted with gangli- 
osides The purified ganghosides were recovered from the clear super- 
nate and stored under N2 at -20°C 
Ganghosides were quantttated as nmol hptd-bound siahc acid 
(LBSA) by the modified calorimetric resorcmol assay [ZO]. High-per- 
formance thm-layer chromatography (HPTLC) of gangliosides was 
performed usmg 10 x 20 cm precoated Silica Gel-60 HPTLC plates (E. 
Merck, Darmstadt. Germany) Two HPTLC development systems 
were used to separate the glycophingohpids The first was the solvent 
system widely used for ganghoside analysts, C/M/0.25% CaCl? 7HZ0 
(60:40,9. v/v/v) [20] The second. described by Rosner [?l]. IS particu- 
larly suitable for vtsuahzmg highly polar highly complex ganghosides. 
In this method gangliosides are applied to the HPTLC plate which IS 
then warmed for 1 h at 50°C. After cooling, the plates are developed 
by consecutive runs (m the same direction and at 38°C) m two differ- 
ent solvent systems: (a) C/M/l2 mM MgClJl5 N NH,OH (60,37:7,3. 
v/v/v/v). and (b) C/M/l2 mM MgCl: (58:-10:9. v/c/v). Ganghostdes 
here vtsuahzed as purple bands with resorcmaol reagent [22] 
3. RESULTS 
3.1. Hunmn amniotic fluid gungliosides 
In initial experiments we analyzed the total gangli- 
osides of four samples of unseparated amniotic fluid 
obtained at different periods of gestation, using the 
standard ganglioside HPTLC solvent system of C/M/ 
0.25% CaCl,.H20 (60:40:9, v/v/v) (Fig. 2). Only 
traces (< 50 pmol LBSA/ml amniotic fluid) or no re- 
sorcinol- positive (ganglioside) bands were seen in the 
region of migration of most of human brain gangli- 
osides in this solvent system (i.e. between G,, and 
G,,,). However, a very densely staining resorcinol-pos- 
itive band is visible near the origin of the HPTLC in 
each of the four amniotic fluid samples (Fig. 2). This 
band has an exceedingly slight but consistent migration 
above the origin of the HPTLC. suggesting that these 
molecules may be very complex gangliosides. To inves- 
tigate these molecules further, we therefore chose a sol- 
vent system which is particularly suitable for resolving 
slowing migrating gangliosides [21]. 
In the first experiment in which we applied this 
method to a sample of pooled amniotic fluid, we de- 
tected a series of four highly complex gangliosides 
which were the main components of this fluid (Fig. 3). 
For comparison, total human brain and plasma gangli- 
osides are shown, demonstrating the strikingly slower 
migration of the human amniotic fluid gangliosides. all 
more polar than G,,,. The gangliosidic nature of these 
resorcinol-positive molecules was further supported by 
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Ftg. 1. Separation of amniotic fluid fractions. 
the detection of sphingosine by positive ion FAB mass 
spectrometry after acid hydrolysis [23] of the total gan- 
glioside extract (not shown). Significantly, G,,, the 
most prevalent extraneural ganglioside. was undetecta- 
ble in the amniotic fluid. This experiment gave the first 
suggestion that human amniotic Auid is characterized 
by an easily visible concentration of highly complex 
gangliosides, and a paucity of the usually prevalent ex- 
traneural ganglioside, GSI. 
3.2. Changes in i~~~mm arnnioticjuid ganglioside content 
btsitfi gestationul uge 
Seventeen human amniotic samples, freshly obtained 
and immediately clarified by centrifugation, were stud- 
ied to determine the range of ganglioside concentration 
in human amniotic fluid. and the effect of gestational 
age. Table I shows that the ganglioside concentration 
in amniotic fluid increases at least fourfold from the first 
trimester of pregnancy until term. with the median con- 
centration rising from 0.2 ,DM LBSA at 16 weeks to 0.8 
PM LBSA at the end of pregnancy. 
To determine whether the total ganglioside composi- 
tion undergoes qualitative change with increasing gesta- 
tional age. the total gangliosides isolated from amniotic 
--GM3 
: \, 
;” 
GDla- 
r*&k 
G Qlb- Oscx __. 
HBG 16 17 28 36 HPG 
AF, Weeks Gestation 
Fig. 2. Ammotic fluid ganghostdes. Total purified ammotic fluid gan- 
ghosides (AF) were separated by HPTLC usmg the solvent system, 
C/M/0.15% CaClz.2HZ0 (60.40.9, v/v/v). 2-5 nmol were spotted per 
lane. HBG. human bram standard gangliostdes; HPG. human plasma 
ganghosides. All bands were resorcmol-posttive. 
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Ftg. 3. HPTLC separatton of highly polar amniotic fluid gangliosides. 
4 nmol total human amniotic fluid gangliosides were separated by 
development of the plate in C/M/l2 mM MgClJlS N NH,.H:O 
(60:37:7:3, v/v/v/v), followed by C/M/l2 mM MgCl, (58:40,9, v/v/v). 
Abbreviations as m Fig. 2 
fluid obtained at different periods of pregnancy were 
analyzed by the HPTLC method of Rosner [21]. As 
shown in Fig. 4, over the period of gestation studied 
(1640 weeks of pregnancy), the pattern of amniotic 
fluid gangliosides is constant. Furthermore, there are 
not more than traces of simple ganglioside such as G,? 
in amniotic fluid. The striking constancy of individual 
species from the first sample (16 weeks) to the final 
sample (end of pregnancy) suggest that the production 
of these highly complex gangliosides continues. without 
qualitative change, throughout pregnancy. 
3.3. Gangliosides of amniotic fluid cellular components 
and surfactant 
The above studies detecting complex gangliosides 
were performed on amniotic fluid which had been clar- 
ified by centrifugation to assure that gangliosides iso- 
lated were not associated with cellular or other particu- 
late matter contained in amniotic fluid. Removed from 
the amniotic fluid in this process are centrifugation pel- 
lets (which include epithelial cells and cell fragments) 
and sometimes a floating lower density fraction, proba- 
bly surfactant, especially visible in the case of samples 
obtained at term. Gangliosides from these two minor 
fractions. comprised at most only a few percent of the 
total amniotic fluid gangliosides. However, these frac- 
tions yielded a surprising pattern (Fig. 5); in contrast to 
the amniotic fluid gangliosides (complex), the predomi- 
nant ganglioside in each of these fractions was G,,. 
Table I 
Ganghostde concentration of amniotic fluid: Effect of gestational age 
Gestattonal Age 
(weeks) 
1&17(n=4) 
27-29 (n = 4) 
3435 (n = 2) 
3640 (?I = 7) 
Gangliosides @M) 
Mean Range 
0.2 0.1-0.3 
0.5 < 0.1~1.0 
0.4 0.3. 0.4 
0.8 0.4-l .3 
Only traces of the complex gangliosides predominant in 
the clarified fluid were detected in the cell pellets and the 
surfactant. Therefore, the major complex gangliosides 
of amniotic fluid are not related to those of surfactant 
or of epithelial cells found in the fluid. 
4. DISCUSSION 
Tissue gangliosides of the fetal-maternal system, in- 
cluding of placenta [13-l 51, placental syncytiotropho- 
blast [24] and meconium [25,26], have been character- 
ized. Several glycoconjugates have been identified in 
amniotic fluid (e.g. lactosylceramide [27], blood group 
I and i antigens [28] and galactosyloligosaccharides 
[29]), but little is known about the gangliosides, which 
are difficult to purify when present only at low concen- 
trations. The major finding of this study was that the 
major gangliosides of human amniotic fluid are a series 
of highly polar and complex molecules. This is surpris- 
ing because the major ganglioside of placenta is G,, 
[13-l 51 and no other normal human tissue or fluid is 
known to have these highly complex gangliosides as 
major components. 
The origin of complex gangliosides in human amni- 
otic fluid is unknown. Amniotic fluid cells (epithelial 
cells) are excluded as a likely source by our studies 
because the major ganglioside of these cells is GM3 [30], 
and the complex gangliosides found in amniotic fluid 
were absent in the cell fraction. The same is true of 
surfactant. Human placenta does contain trace amounts 
of several highly polar neolacto series gangliosides 
[15.31,32]. migrating near the origin by standard 
HPTLC. Syncytiotrophoblast and amnion also contain 
such complex molecules [ 16,24,33]. Therefore, these tis- 
sues could be the origin of the highly complex gangli- 
osides in amniotic fluid. By the process of shedding, 
these molecules could accumulate and concentrate in 
amniotic fluid during gestation. 
What is the potential significance of the finding of 
-GM3 
-GDZ 
-GTlb 
HBG ,I6 27 28 36, HPG 
AF, Weeks Gestation 
Fig. 4. Effect of gestational age upon human amniotic fluid gangli- 
ostde Samples obtamed in each trtmester were purtfied and compared. 
Abbrevtations as in Fig. 2. Solvent system: as m Fig. 3. 
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Fig 5. Ganghostdes of amniotic fluid fracttons. Gangliosides of the 
cellular components (P, and P,) and surfactant (S) are compared to 
those of the clarified ammotic fluid. Solvent system: as m Fig. 3. 
these highly polar gangliosides in human amniotic 
fluid? Amniotic fluid has a strategy disposition near the 
maternal-fetal interface and is continuously circulating 
through the fetus; soluble factors secreted or shed at this 
interface could therefore be concentrated in the fluid. In 
fact, several soluble immunologically active proteins or 
glycoproteins secreted by the tissues of this interface 
have been isolated [34,35]. and both murine [6,7.9,10] 
and human [8.36] amniotic fluid have immunosuppres- 
sive properties. The total lipid extract of crude human 
amniotic fluid (which would contain any gangliosides) 
also inhibits [‘Hlthymidine uptake by PHA-activated 
human peripheral blood mononuclear leukocytes [36]. 
as do the lipid components of the syncytiotrophoblast 
plasma membrane [37]. We speculate that the complex 
gangliosides we detected contribute to immunosuppres- 
sive activity of human amniotic fluid. Proof of this hy- 
pothesis will now entail the preparative purification of 
these molecules for determination of their structures 
and immunoregulatory activity. 
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